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A cohort of 1792 human immunodeficiency virus (HIV)–positive and 2970 HIV-negative South African miners
was observed for 12 months starting in February 1998. All-cause hospitalizations and deaths were significantly
associated with HIV infection (respective unadjusted incidence rate ratios, 2.9 and 9.2; respective 95% con-
fidence intervals, 2.5–3.4 and 5.5–16.0). Tuberculosis (TB), bacterial pneumonia, cryptococcosis, and trauma
were the major causes of admission for HIV-positive patients, whereas Pneumocystis carinii pneumonia was
an uncommon cause (respective admission rates, 8.5, 6.9, 2.2, 6.0, and 0.53 admissions per 100 person-years).
Enteritis, bronchitis, urinary tract infections, and soft-tissue infections were also significantly associated with
HIV infection. Cryptococcosis caused 44% of deaths among HIV-positive patients. Trauma was the main
hazard for HIV-negative men, causing 42% of admissions and 60% of deaths. A broad range of infectious
conditions is significantly associated with HIV infection in South African miners. Identification and imple-
mentation of effective prophylactic regimens are urgently needed.
In 7 countries in the southern region of Africa, the es-
timated prevalence of HIV infection among adults was
20% by the end of the year 2000 [1], which inevitably
translated into a huge increase in the need for health
care. Despite the gravity of the situation, research into
the clinical aspects of HIV infection in southern Africa
has not been prioritized, and the natural history of HIV
infection in the region remains poorly characterized [2].
A clear understanding of how HIV affects the frequency
and etiology of common illnesses facilitates good clinical
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management, points the way to interventions likely to
reduce HIV infection–associated morbidity and mortal-
ity rates, and provides a firm basis for advocacy and
planning.
We report a prospective cohort study that compared
hospitalization and mortality rates between HIV-posi-
tive and HIV-negative South African gold miners. Dur-
ing follow-up, the prevalence of HIV infection was 24%
in the workforce evaluated [3], which primarily in-
cluded male migrant workers living in single-sex hos-
tels. Rates of trauma, sexually transmitted disease
(STD), and silica-associated occupational disease are
high [4, 5]. In recent years, the incidence of tuberculosis
(TB) has increased to extremely high rates (figure 1)
as a result of the combined effects of the HIV epidemic
and the exposure to silica dust [8, 9]. The main aims
of the study were to quantify the impact of HIV in-
fection on the incidence and spectrum of diseases lead-
ing to hospitalization or death and to assess the scope
for preventive interventions in this population.
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Figure 1. Time trend in tuberculosis (TB) case notification rates among
the study workforce of South African gold miners, compared with the
rates for the general population of the United States. Figures for the
United States are from the World Health Organization [6]. Workforce TB
figures are from the Chamber of Mines, South Africa [7].
METHODS
Study population and cohort selection. In South Africa, gold
miners are provided with private medical care at company-
funded hospitals and clinics. In the study hospital (Ernest Op-
penheimer Hospital; Welkom), HIV testing has been offered,
since 1991, to all patients presenting with HIV-associated con-
ditions; consent is obtained from all miners, and pre- and
posttest counseling is available. Hospital laboratory and payroll
records were used to identify all current employees who had
been tested for HIV since 1991. All men who had tested positive
for HIV were included in the study, as were men who had
tested negative for HIV because of an STD in 1994 or later.
The cutoff date was imposed because of the increasing cu-
mulative risk of new HIV infection as time passed after a neg-
ative HIV test result was obtained. Additional HIV testing to
confirm negative status was not performed because of logistic
and financial constraints. However, miners who presented with
HIV-associated conditions during follow-up were asked to con-
sent to retesting. Miners provided informed consent and re-
ceived pre- and posttest counseling; they were excluded from
the final analysis if they were subsequently found to be HIV
positive. Participants who declined retesting were assumed to
have remained HIV negative.
Cohort follow-up. Cohort subjects were observed for 12
months, starting in February 1998; we assessed admission to
the study hospital and/or death. Admissions to other facilities
were identified when emergency transfers were requested. How-
ever, because the town in which the study took place (Welkom)
was geographically isolated, and because the hospital was the
only source of free health care and sickness benefits, use of
other inpatient facilities was minimal. Hospitalized participants
were interviewed and examined according to a standardized
protocol, and they were observed until discharge from the hos-
pital or death. HIV-positive participants were asked to provide
consent for measurement of their CD4 T lymphocyte count.
Gold miners who left employment or died were periodically
identified by review of payroll, death benefit, and mortuary
records. Routine heart and lung postmortem examinations for
occupational diseases were performed for men who died in the
hospital or in the vicinity of the mine. Postmortem findings
were reviewed by the senior histopathologist at the National
Centre for Occupational Health (Johannesburg).
Laboratory methods. CD4 T lymphocyte counts were
measured by flow cytometry (FACScan; Becton Dickinson).
Microscopic evaluation for TB was performed with auramine
staining of concentrated specimens. Mycobacterial culture was
performed using Lowenstein-Jensen slopes for sputum speci-
mens and BACTEC (Becton Dickinson) liquid media for other
specimens. Mycobacterium tuberculosis was identified with a
colorimetric ribosomal RNA hybridization test (AccuProbe M.
tuberculosis complex probe kit; Gen-Probe). Bacterial pathogens
were identified by Gram staining and biochemical testing done
after culture was performed with conventional media. Fungal
identification was done by use of India ink contrast staining
and microscopic evaluation, culture with Sabouraud media,
and, for diluted blood or CSF specimens, latex agglutination
testing for cryptococcal antigens. Pneumocystis carinii infection
was diagnosed by microscopic evaluation of specimens stained
with Grocott-Gomori methenamine–silver nitrate.
Case definitions. The main reason for admission to the
hospital was determined for each patient on the basis of pre-
defined case definitions (not detailed here) that incorporated
clinical, radiologic, laboratory, and, if relevant, postmortem
findings. The 1993 Centers for Disease Control and Prevention
case definition for AIDS was followed, except that CD4 cell
count criteria were not used [10].
Ethical considerations. The study was approved by the
ethics committees of the London School of Hygiene and Trop-
ical Medicine (London) and the Ernest Oppenheimer Hospital
(Welkom, South Africa). To maintain confidentiality, consent
to participate in the study was obtained from hospitalized pa-
tients before their HIV test results were referenced. Additional
testing and counseling were freely available.
Data analysis. Data were analyzed with Stata software,
version 7.0 (Stata Corporation). Patient records were expanded
into person-year follow-up records, according to each patient’s
age and reason for hospital admission. For all gold miners,
separate records were created for each period between entry
into the cohort and first admission (where relevant), between
any subsequent hospital admissions, and then from last event
to the end of the follow-up period. Poisson regression was used
to calculate univariate incidence rate ratios (IRRs) from the
expanded data set. For analyses in which multiple events were
possible, random rate multipliers (assumed to follow a g dis-
tribution) were used to adjust rate ratio and 95% CI estimates
for individual “frailty” effects, because rehospitalization rates
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Table 1. Baseline characteristics of South African gold miners
and events that occurred during follow-up.
Characteristic or event
HIV-positive
patients
(n p 1792)
HIV-negative
patients
(n p 2970)
Age, mean years  SD 37.9  7.2 37.7  7.1
Time employed as a miner, mean
years  SD 14.4  7.8 14.5  7.5
No. of person-years (mean no. per
subject) 1498 (0.84) 2590 (0.87)
Admission to the hospital 453 (25) 311 (10)
2 hospitalizations during follow-up 108 (6) 40 (1.3)
Death 82 (5) 15 (0.5)
Left employmenta 275 (15) 395 (13)
NOTE. Data are no. (%) of patients, unless otherwise indicated. No. of
patients reflects cohort selection methods.
a For reasons other than death.
were significantly greater than predicted by the Poisson distri-
bution alone. Otherwise, IRRs were not adjusted.
For variables with 12 categories, tests for trend were cal-
culated using likelihood-ratio tests. The Mann-Whitney test was
used to test differences in CD4 T lymphocyte counts for sig-
nificance between subgroups of HIV-positive patients, accord-
ing to admission and outcome categories.
RESULTS
The final cohort comprised 1792 HIV-positive men (38%) and
2970 HIV-negative men (62%). Baseline characteristics and co-
hort events are shown in table 1. The rate of leaving employ-
ment was significantly higher among HIV-positive employees
than it was among HIV-negative employees (18.4 and 15.3
persons left employment per 100 person-years, respectively;
IRR, 1.2; 95% CI, 1.03–1.4), but there were no significant dif-
ferences in age or duration of employment.
Hospitalization rates among HIV-negative gold miners.
There were 363 admissions to the hospital among HIV-negative
men, for a rate of 14 hospitalizations per 100 person-years.
Information about the hospitalizations is listed in table 2, and
the main causes are illustrated in figure 2. Most admissions
were related to trauma. Of the patients included in the final
analysis, all of those with pneumonia and enteritis and all but
2 with TB (who declined additional testing) were confirmed
to be HIV negative at admission.
Hospitalization rates among HIV-positive miners. For
HIV-positive men, there were 599 admissions to the hospital.
The overall rate was significantly higher than that for HIV-neg-
ative men (40.0 admissions to the hospital per 100 person-years;
IRR, 2.9; 95% CI, 2.5–3.4). Infectious diseases were responsible
for 70% of admissions to the hospital for HIV-positive men, as
opposed to 30% of the admissions for HIV-negative men (P !
). Incidence rates and rate ratios are shown in table 2, and.001
the main causes are illustrated in figure 2.
The most frequent reasons for hospitalization of members
of the HIV-positive cohort were TB (8.5 hospitalizations per
100 person-years), acute pneumonia (6.9 per 100 person-years),
cryptococcosis (2.2 per 100 person-years), and trauma (6.0 per
100 person-years). P. carinii pneumonia (PCP) was uncommon,
and there was only 1 diagnosis of HIV wasting syndrome. Ad-
missions to the hospital because of TB, acute pneumonia, bron-
chitis, enteritis, soft-tissue infections, urinary tract infections,
cryptococcosis, PCP, or conditions due to viral infections were
each significantly associated with HIV infection (table 2).
CD4 T lymphocyte counts are shown, according to cause
and outcome of admission, in figure 3. Not all HIV-positive
men consented to provide additional blood samples to allow
us to test for CD4 T lymphocyte counts. CD4 T lymphocyte
counts in HIV-positive men with TB were significantly higher
( ) than were counts for patients with cryptococcal diseaseP ! .01
or other AIDS-defining diagnoses, but they did not differ sig-
nificantly from the CD4 T lymphocyte counts for patients
with pneumonia or enteritis. The highest CD4 T lymphocyte
counts were in trauma and surgical patients.
Rehospitalizations. Rehospitalization rates were signifi-
cantly higher than the incidence rate for first admissions (for
HIV-positive men with and without a previous admission dur-
ing the study, 75 and 35 rehospitalizations per 100 person-
years, respectively; IRR, 2.18; 95% CI, 1.8–2.6). Infections were
again the predominant cause (106 [70%] of 151 rehospitali-
zations and 317 [70%] of 448 first admissions), but pneumonia,
rather than TB, was the most common cause among HIV-
positive men (38 [25%] and 12 [8%] of the 151 recurrent
admissions, respectively).
Rate and main causes of death. The rate of death was
significantly higher among HIV-positive men than it was among
HIV-negative men (5.5 and 0.6 deaths per 100 person-years,
respectively; IRR, 9.2; 95% CI, 5.5–16.0). Cause of death, ac-
cording to HIV infection status, is illustrated in figure 4. The
most common causes of death were cryptococcal disease, in
HIV-positive men, and trauma, in HIV-negative men. Post-
mortem examination was performed for 51 (62%) of 82 HIV-
positive patients who died and for 14 (93%) of 15 HIV-negative
patients who died. HIV-positive men who died after being ad-
mitted to the hospital or within 2 weeks of discharge (defined
as a fatal outcome for that admission) had significantly lower
CD4 T lymphocyte counts than did those with nonfatal out-
comes (respective median CD4 T lymphocyte counts, 36 and
cells/L; ). Overall, 7.7% of HIV-positive pa-6209 10 P ! .001
tients and 3.6% of HIV-negative patients admitted to the hos-
pital died ( ).Pp .01
Disease-specific microbiologic data and clinical presenta-
tion. Data regarding relevant isolates recovered from patients
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Table 2. Impact of HIV infection on rates of admission to the hospital for different conditions.
Condition
No. of admissions
Admission rates
per 100 person-years
IRR (95% CI)a
HIV-positive
patients
HIV-negative
patients
HIV-positive
patients
HIV-negative
patients
Mycobacterial disease
Tuberculosis 128 15 8.5 0.58 14.8 (8.7–25.2)
Mycobacterium kansasii diseaseb 3 3 0.20 0.12 1.7 (0.3–8.6)
Bacterial infection
Acute pneumoniac 103 5 6.9 0.19 35.9 (14.5–89.0)
Enteritis 27 7 1.8 0.27 6.7 (2.9–15.5)
Traumatic wound infection 19 19 1.3 0.73 1.7 (0.9–3.4)
Bronchitisd 17 7 1.1 0.27 4.2 (1.7–10.1)
Urinary tract infection 14 2 0.93 0.08 12.1 (2.6–56.6)
Perianal abscess 13 10 0.87 0.39 2.3 (0.9–5.8)
Spontaneous soft-tissue infectione 12 7 0.80 0.27 3.0 (1.2–7.5)
Ear, nose, and throat infections 10 12 0.67 0.46 1.4 (0.6–3.5)
Otherf 5 4 0.33 0.15 2.2 (0.6–8.0)
Fungal infection
Cryptococcosis 33 0 2.2 0  (—)g
Pneumocystis carinii pneumonia 8 0 0.53 0  (—)g
Esophageal candidiasis 1 0 0.07 0  (—)h
Other infection
Parasitici 6 12 0.40 0.46 0.8 (0.3–2.5)
Viralj 15 6 1.0 0.23 4.3 (1.6–11.5)
Self-limiting fever 2 1 0.13 0.04 3.5 (0.3–38.1)
Other AIDS-defining diagnosesk 3 0 0.20 — — (—)
Other medical causes 49 56 3.3 2.2 1.5 (0.9–2.5)
Traumatic injury
Occupational 38 78 2.5 3.0 0.8 (0.6–1.2)
Nonoccupational 39 47 2.6 1.8 1.4 (0.9–2.2)
Later complicationsl 14 25 0.93 0.97 1.0 (0.5–1.9)
Other surgical causes 30 45 2.0 1.7 1.2 (0.7–1.9)
Totalm 599 363 40.0 14.0 2.9 (2.5–3.4)
NOTE. IRR, incidence rate ratio.
a Adjusted for overdispersion if recurrent admissions were possible (see the data analysis subsection in the Methods
section).
b All pulmonary M. kansasii disease, which is associated with mining in South Africa.
c Includes 16 admissions to the hospital for recurrent pneumonia in 14 HIV-positive men.
d Distinguished from pneumonia by absence of radiographic changes.
e Includes cellulitis, erysipelas, and a single case of necrotizing fasciitis.
f Includes intra-abdominal sepsis, chancroid, gastritis due to Helicobacter species, and neurosyphilis.
g .Pp .001
h .Pp .16
i Includes malaria, neurocysticercosis, and urinary schistosomiasis.
j Includes chickenpox, shingles, acute hepatitis B virus infection, genital warts, and genital herpes.
k Includes 1 patient with cerebral space-occupying lesion that did not respond to toxoplasmosis treatment, 1 with HIV
encephalopathy, and 1 with HIV wasting syndrome.
l Does not include wound infections.
m Includes admissions to the hospital for an additional 10 HIV-positive and 2 HIV-negative patients not categorized
above (2 admissions for palliative care for progression of cryptococcal disease, and 10 admissions for episodes of suspected
tuberculosis that did not meet the study case definitions).
with TB, cryptococcosis, pneumonia, and enteritis, according
to the patient’s HIV infection status, are shown in table 3. The
most frequently identified pathogens in HIV-positive men were
M. tuberculosis, pneumococcus, and Cryptococcus species.
Seroconversion in the HIV-negative group. As detailed in
the Methods section, the interval between the date that a negative
HIV test result was obtained and the start of the study was as
long as 5 years for some men, so that some men had become
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Figure 2. Causes of hospitalization, according to HIV infection status.
See table 2 for numbers of admissions and incidence rates. ADD, AIDS-
defining diagnoses; MK, Mycobacterium kansasii disease; PCP, Pneu-
mocystis carinii pneumonia; TB, tuberculosis.
Figure 3. Box-and-whisker plot showing median and range of CD4
T lymphocyte counts, according to cause and outcome of admission. Lower
and upper line bars show the minimum and maximum CD4 T lymphocyte
counts recorded for each admission category, up to a maximum of
cells/L. The lower, middle, and upper points on the solid bars61000 10
denote the 25th percentile, median, and 75th percentile, respectively.
Median values are also shown in parentheses after the admission cat-
egories. Values were based on CD4 T lymphocyte counts recorded at
admission to the hospital for 114 patients with tuberculosis (TB; 89%);
96 patients with pneumonia (93%); 28 patients with cryptococcal disease
(85%); 23 patients with enteritis (85%); 10 patients with other AIDS-
defining conditions (83%); 47 patients with other bacterial infections
(52%); 7 patients with viral infections (47%); 33 patients with other
medical conditions (67%); 32 patients with trauma (42%; not including
complications); 11 patients with other surgical conditions (37%); and
patients who were admitted to the hospital who had fatal (33 patients
[72%]) and nonfatal (395 patients [71%]) outcomes, respectively.
HIV infected during this interval. As discussed in the Methods
section, the admission and person-years data from men who
were initially included in the HIV-negative arm of the cohort,
but who were subsequently found to be HIV positive, were ex-
cluded from the final analysis. Altogether, 201 men (6% of the
3172 men initially selected into the HIV-negative cohort) and
187 (7% of a total of 2777 person-years observed for the initially
selected HIV-negative cohort) were excluded because of a positive
HIV test result obtained during the study period.
In most cases (123 [61%] of 201), the indication for addi-
tional HIV testing was for a symptomatic STD, and retesting
was performed during outpatient clinic visits. For the remaining
78 patients (39%), however, the indication for retesting was
because of admission to the hospital with an HIV-associated
condition. Men with previously unidentified seroconversion to
HIV-positive status accounted for 16 pneumonia admissions,
26 TB admissions, and 3 cryptococcal disease admissions. If
we assume that hospitalization for HIV-associated diseases oc-
curred at the same rate as that for the HIV-positive cohort,
then the admission data from excluded men can be used to
provide estimates of the total HIV prevalence for men in the
initially selected HIV-negative cohort. For example, if the rate
of admissions for cryptococcal disease was 2.2 admissions per
100 person-years for all HIV-positive miners, then 136 HIV-
positive person-years of follow-up would be required to pro-
duce the 3 persons admitted from the initially selected HIV-
negative cohort. This allows us to estimate that 5% (136 of
2777 person-years of observation) of the initially selected HIV-
negative cohort was, in fact, HIV positive. Equivalent calcu-
lations for TB and pneumonia give estimates of HIV prevalence
of 11% (306 of 2777 person-years) and 10% (275 of 2777) in
the initially selected HIV-negative cohort. Because 6% of the
initially selected HIV-negative cohort and 7% of the person-
years of observation were identified as being HIV positive and
were excluded from the final analysis, then the aforementioned
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Figure 4. Cause of death, according to HIV infection status. ADD,
AIDS-defining diagnoses; PCP, Pneumocystis carinii pneumonia; TB,
tuberculosis.
Table 3. Disease-specific microbiologic findings, according
to HIV infection status.
Disease and isolate
HIV-positive
patients
HIV-negative
patients
Tuberculosis
No. of cases 128 15
Smear and culture negative 9 (7) 0 (0)
Smear positive, culture nega-
tive, or not done 20 (16) 3 (20)
Smear negative, culture positive 23 (18) 1 (7)
Smear and culture positive 76 (59) 11 (73)
Cryptococcosis
No. of cases 33 0
Culture positive 26 (79) —
Antigen positive, culture
negative 4 (12) —
Biopsy or postmortem
diagnosis 3 (9) —
Pneumonia
No. of cases 103 5
Pneumococcus 32 (31) 1 (20)
Haemophilus influenzae 8 (8) 0 (0)
Klebsiella species 5 (5) 0 (0)
Pseudomonas species 2 (2) 0 (0)
Staphylococcus aureus 1 (1) 0 (0)
Escherichia coli 1 (1) 0 (0)
None 54 (52) 4 (80)
Enteritis
No. of cases 27 7
Salmonella species 5 (19) 0 (0)
Shigella species 3 (11) 1 (14)
Cryptosporidia 1 (4) 0 (0)
None 18 (67) 6 (86)
NOTE. Data are no. (%) of episodes of respective disease, unless oth-
erwise indicated.
estimated range of HIV prevalence of 5% to 11% suggests that
most of the HIV-positive men were identified during the study
year.
DISCUSSION
This study describes the impact of HIV infection on the in-
cidence and spectrum of disease in South African gold miners.
HIV infection greatly increased rates of hospitalization and
death as a result of significantly increased rates of a range of
different infectious diseases. TB was the single most common
cause of hospitalization for the HIV-positive cohort. The grave
consequences of the HIV epidemic on TB control at the work-
force level are shown in figure 1 [6, 7]. Bacterial pneumonia,
cryptococcal disease, and acute enteritis were also important
HIV-associated opportunistic infections, with cryptococcal dis-
ease being the most common cause of death.
There are both similarities to and differences with other stud-
ies of HIV-associated disease in Africans [2, 11–24]. Greatly
increased rates of TB and bacterial pneumonia are consistently
associated with HIV disease in Africa, although there is an extra
occupational component to TB in gold miners because of their
exposure to silica dust [9], and rates of pneumococcal disease
in newly recruited miners were high even before the HIV epi-
demic [25]. Rates of acute pneumonia as variable as 9.3 [19],
3.0 [23], and 1.8 [18] cases per 100 person-years were observed
in the placebo arms of 3 randomized, controlled trials involving
HIV-positive Africans. Two of these trials investigated treatment
with cotrimoxazole in Abidjan, Cote d’Ivoire [18, 19], and the
other trial studied pneumococcal vaccination in Ugandans [23].
Important differences in ascertainment are likely to have ex-
isted, however, because 2 of the studies included outpatients
[19, 23], whereas the study with the lowest rate of acute pneu-
monia included hospitalized patients only [18].
Acute enteritis was the most common gastrointestinal com-
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plaint and was significantly associated with HIV infection.
Chronic diarrhea, wasting syndrome, and enteric fever–like ill-
ness due to nontyphoidal Salmonella species are among the most
common serious illnesses noted in studies of HIV infection from
other parts of Africa [11, 13, 15, 18–20], but this was not the
case in the present study. The relative scarcity of gastrointestinal
symptoms in the current study may reflect regional differences,
or it may indicate that sanitation and water supplies in gold
mines are unusually good for Africa. PCP and pulmonary Ka-
posi’s sarcoma both occurred, albeit at low rates, and other AIDS-
defining conditions, such as cerebral toxoplasmosis, cyto-
megalovirus disease, and disseminated Mycobacterium avium
intracellulare, were notable for their absence, despite the avail-
ability of appropriate diagnostic facilities and expertise.
Overall mortality rates and the relative risk of death for HIV-
positive gold miners in this study were within the range ob-
served in other African cohorts [15, 21, 22, 24, 26], but at the
lower end. The high proportion of deaths due to cryptococcosis
is noteworthy. Although there are no other regional incidence
estimates, a high risk of cryptococcal disease appears to be a
general feature of HIV in southern Africa [27–30] that is not
shared throughout the continent. Absolute incidence rates of
cryptococcosis were !1 case per 100 person-years, and crypto-
coccosis was responsible for a much lower proportion of hos-
pital admissions and deaths in both of the Abidjan co-
trimoxazole trial cohorts [18, 19] and in rural Uganda [20].
The main strengths of this study are its unusually large size,
inclusion of both HIV-positive and HIV-negative cohorts, and
unusually good diagnostic facilities plus a high coverage of
postmortem examinations. These factors have enabled us to
develop an unusually detailed description of the situation, with
the impact of HIV infection clearly distinguished from that of
HIV-negative disease. The main limitations of our report are
the unusual population studied, which may well have altered
the spectrum of disease seen, and the reliance on routine clinical
services. We estimate that 6%–9% of the HIV-negative patients
in our study had acquired HIV infection after their initial HIV
test, but not all of these patients were identified and excluded
during follow-up. This may have artificially increased our es-
timated rates of disease among HIV-negative patients, thereby
underestimating the impact of HIV infection, although the po-
tential for this was minimized by the high consent rates to
retesting of patients with strongly HIV-related conditions.
There is likely to have been a substantial “healthy worker” effect
in our HIV-positive cohort, because the rate of leaving em-
ployment increased once workers became symptomatic, leading
to reduced disease rates. On the other hand, our HIV-positive
cohort was made up of prevalent (rather than incident) cases,
including individuals identified through symptomatic HIV dis-
ease as well as STDs, resulting in an opposing bias toward
inclusion of individuals with more-advanced HIV disease.
HIV prevalence in the study workforce was 24% by 1999 [3].
Our observed rates of hospital admission and death imply that,
by 1999, general workforce death rates had tripled as a conse-
quence of the HIV epidemic, and the rates of hospital admission
had increased 1.5-fold. The scale of the impact of untreated HIV
infection at such a high prevalence, and the huge toll from prev-
entable opportunistic infections, such as TB [31], bacterial in-
fections [18, 19], and cryptococcosis [32], greatly exceed the level
of uncertainty surrounding these estimates. After completion of
this study, routine outpatient clinics offering isoniazid and co-
trimoxazole prophylaxis have been started, and provision of ad-
ditional therapies, including highly active antiretroviral drugs and
prophylactic fluconazole, is now being considered. Increased ac-
cess to the means of HIV diagnosis and treatment is urgently
required throughout southern Africa.
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